A leukemic target with a thousand faces: The mitochondria
B Maffeo, C Panuzzo, A Moraca, D Cilloni - International Journal of …, 2023 - mdpi.com
In the era of personalized medicine greatly improved by molecular diagnosis and tailor-
made therapies, the survival rate of acute myeloid leukemia (AML) at 5 years remains …
made therapies, the survival rate of acute myeloid leukemia (AML) at 5 years remains …
[HTML][HTML] Integrated stress response activation induced by usnic acid alleviates BCL-2 inhibitor ABT-199 resistance in acute myeloid leukemia
D Wu, M Li, Y Hong, L Jin, Q Liu, C Sun, L Li… - Journal of Advanced …, 2024 - Elsevier
Abstract Introduction ABT-199 (venetoclax) is a BCL-2 suppressor with pronounced effects
on acute myeloid leukemia (AML). However, its usefulness as a monotherapy or in …
on acute myeloid leukemia (AML). However, its usefulness as a monotherapy or in …
GATA2 links stemness to chemotherapy resistance in acute myeloid leukemia.
Stemness-associated cell states are linked to chemotherapy resistance in AML. We
uncovered a direct mechanistic link between expression of the stem cell transcription factor …
uncovered a direct mechanistic link between expression of the stem cell transcription factor …
Enhancing the Antileukemic Activity of the Bcl-2 Inhibitor, Venetoclax, Against Acute Myeloid Leukemia
KH Hurrish - 2023 - search.proquest.com
The 5-year overall survival rate for adults with acute myeloid leukemia (AML) is only 27%
and most new patients cannot tolerate the intensive standard chemotherapy. Although the …
and most new patients cannot tolerate the intensive standard chemotherapy. Although the …